Introduction
============

Fluorine-18 fludeoxyglucose (FDG) positron emission tomography (PET) is a well established diagnostic modality for standard oncological staging, restaging, and treatment monitoring evaluations, and has a major impact on patient management \[[@B1]-[@B3]\]. A key issue that is less well studied is the performance of FDG-PET in accurately depicting bone metastases that would potentially have a large effect on patient treatment \[[@B2],[@B4]\]. Metastases to the spine represent a common problem in large oncology centers and usually present a problem in radiological diagnosis. The role of PET is still being assessed in this context.

However, molecular imaging (MI) with FDG-PET seems a good additional state-of-the-art method to demonstrate the viability of previously treated spinal tumor metastasis or to differentiate malignant from benign lesions in the spine \[[@B2],[@B4]\]. Additionally, PET may help to find the sites of the most metabolic active lesions for biopsy \[[@B2],[@B5]\]. In thyroid cancer, PET MI is useful in patients with metastatic poorly differentiated tumors with high thyroglobulin (Tg) levels and negative ^131^I whole-body scan results \[[@B6],[@B7]\].

Similar to the situation with other tumor types, it is currently unclear whether FDG-PET is adequate in the detection of bone metastasis of thyroid cancer. We describe one of the very few reported clinical cases with vertebral metastases of a less well differentiated follicular thyroid carcinoma followed by FDG-PET and I-131 single photon emission computer tomography (SPECT). The unique feature of this case is that the follow-up was performed by FDG-PET and SPECT, and we can therefore compare the results of these two MI modalities. MI by FDG-PET helped to exclude a metabolically active spinal metastasis.

Case report
===========

We present the case of a 50-year-old Caucasian woman with a vertebral metastasis of a less well differentiated thyroid cancer, who was followed over a three-year period clinically and by spinal FDG-PET and I-131 SPECT imaging after initial surgery. Table [1](#T1){ref-type="table"} chronologically summarizes the treatment modalities, corresponding laboratory test values (thryotropin (TSH) and Tg level) and MI results (FDG-PET and I-131 SPECT) for different time points during follow-up.

###### 

Treatment modalities, corresponding laboratory values (TSH and Tg level) and MI results (FDG-PET and I-131 SPECT) for different time points during follow-up

  Parameter              Date (MM/YY format) and treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  ---------------------- ----------------------------------------- --------------------- --------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------- --------------
  Treatment              Cementoplasty and posterior arthrodesis   Total thyroidectomy   First RIT (GBq level unknown)                                                                             Second RIT (GBq level unknown)                                                                       Third RIT (5.4 GBq)                                                                                                            Fourth RIT (5.5 GBq)                                                                                                           Fifth RIT (5.8 GBq)                                                                                                            Wait and see                                                                Wait and see
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  TSH (mIU/L)            NA                                        NA                    NA                                                                                                        NA                                                                                                   103                                                                                                                            119                                                                                                                            130                                                                                                                            NA                                                                          \< 0.02
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Thyroglobulin (μg/L)   NA                                        NA                    2357                                                                                                      805                                                                                                  891                                                                                                                            1035                                                                                                                           939                                                                                                                            NA                                                                          606
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  I-131 SPECT            NA                                        NA                    Positive uptake: thyroid bed, multiple foci in the lungs, osseous lesions T11, L3, os ilium, left femur   No uptake in the thyroid bed, decreasing uptake in the lungs, stable uptake in the osseous lesions   No uptake in the thyroid bed, os ilium, left femur decreasing uptake in the lungs, stable uptake in the spine lesions T11/L3   No uptake in the thyroid bed, os ilium, left femur decreasing uptake in the lungs, stable uptake in the spine lesions T11/L3   No uptake in the thyroid bed, os ilium, left femur decreasing uptake in the lungs, stable uptake in the spine lesions T11/L3   NA                                                                          NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  FDG-PET                NA                                        NA                    NA                                                                                                        NA                                                                                                   NA                                                                                                                             NA                                                                                                                             Slight uptake in Pulmonary metastases, no uptake in spinal lesions T11/L3                                                      Slight uptake in Pulmonary metastases, no uptake in spinal lesions T11/L3   NA

FDG = fludeoxyglucose; NA = not available; PET = positron emission tomography; RIT = radioiodine treatment; Tg = thyroglobulin; TSH = thryotropin; SPECT = single photon emission computer tomography.

Our patient presented to our facility with progressive spinal cord compression. An MRI scan revealed a vertebral metastasis at the T11 level with intraspinal extension compressing the spinal cord. Our patient was operated on via a bilateral posterolateral approach, allowing for tumor resection and stabilization of her vertebral column by Cementoplasty and a posterior arthrodesis. A histopathological examination concluded \'metastasis of a less well differentiated thyroid carcinoma\', which was confirmed after total thyroidectomy (follicular thyroid carcinoma pT2 pNx). Following her first radioiodine therapy a post-therapeutic scan revealed multiple lung metastases and further bone metastases at the L3 level, os ilium and left femur; therefore the tumor was staged as M1 (lung, bone). During follow-up our patient received five radioiodine therapies (5.3 to 5.7 GBq each) in total over a two-year period.

During the follow-up period our patient was regularly monitored clinically and by means of a tumor marker (thyroglobulin), PET-CT (\[F-18\]-FDG) and post-therapeutic SPECT (I-131). Clinically and neurologically our patient was stable over three years of follow-up. Post-therapeutic radioiodine scans showed decreasing uptake in most Pulmonary lesions but remaining uptake in spine lesions (Figure [1](#F1){ref-type="fig"}). Her stimulated thyroglobulin blood levels dropped from 2356 μg/L at baseline to 939 μg/L following the last radioiodine treatment. However, even after finishing five radioiodine cycles Tg remained on a pathologically increased level, indicating some neoplastic activity. FDG-PET imaging showed slight but remaining hypermetabolism in the lungs whereas in SPECT imaging Pulmonary hyperfixation of I-131 disappeared, most likely indicating dedifferentiation. On the spinal level, SPECT images showed persistent hyperfixation at the operated level (T11) and even higher fixation at the spinal process of L3 (Figure [2](#F2){ref-type="fig"}) suggestive for remaining, more differentiated metastases. FDG-PET, however, showed no hypermetabolism, which correlated with the stable neurological examination results (Figure [3](#F3){ref-type="fig"}).

![**Planar I-131 whole-body scintigraphies after our patient\'s third, fourth and fifth radioiodine treatments, demonstrating decreasing uptake in the pulmonary metastases in the right and left lung parenchyma but stable uptake in the spinal lesions of Th11 and L3**.](1752-1947-5-522-1){#F1}

![**Single photon emission computer tomography (SPECT) I-131-CT demonstrating a persistent hyperfixation at the operated level and even higher fixation at the spinal process of L3**.](1752-1947-5-522-2){#F2}

![**18F-fludeoxyglucose positron emission tomography/computed tomography (FDG-PET-CT) demonstrating hypometabolism at the spinal level correlating with the stable neurological examination**.](1752-1947-5-522-3){#F3}

After thorough interdisciplinary discussion, despite the remaining I-131 uptake it was decided not to operate again on our patient\'s spine as she was completely asymptomatic; conventional imaging also remained stable and the neurological risk seemed to be too high for the thoracic level. During further follow-up our patient remained neurologically stable.

Discussion
==========

Detection of spinal metastasis by MI is a relatively new, but clinically important technique. Cases such as our patient\'s, where the different MI modalities can be directly compared, are important to gain more experience in the different modalities for spinal MI and to perhaps find special indications for the one or the other method. In addition, our case report underlines the usefulness of FDG-PET in assessing the metabolic activity of bone metastasis of less well differentiated thyroid cancer.

In our case report, in which different MI techniques were used for the detection of distant metastases from thyroid cancer, we were able to demonstrate different behavior of the pulmonary and osseous lesions. While the pulmonary nodes presented with decreased radioiodine uptake but increased FDG uptake indicating de-differentiation, the spinal lesions showed stable radioiodine uptake without FDG uptake, most probably indicating stable disease. Subsequently, integrated I-131 SPECT/CT was found to have an additional value compared to planar scintigraphy in patients with thyroid cancer for correct characterization of equivocal tracer uptake seen on planar imaging, as well as for precise localization of malignant lesions in the skeleton \[[@B8],[@B9]\]. In our patient\'s case these combined MI findings justified not operating again on her spine; this turned out to be the right decision, since our patient remained neurologically stable over further follow-up.

The FDG-PET examinations were performed under stimulated TSH conditions to increase the diagnostic sensitivity. It is known that TSH stimulates thyrocyte metabolism, glucose transport and glycolysis. Since FDG is a glucose analog, several studies have shown that recombinant human TSH (rhTSH) stimulation improves the detection of occult thyroid metastases with FDG-PET, compared with scans performed on TSH suppression \[[@B10]\]. Beyond I-131 targeting the OPG/RANK/RANKL axis may offer a novel therapeutic approach for malignant osteolytic pathologies \[[@B11]\], but currently there are no such studies specifically for thyroid cancer bone metastases.

Conclusions
===========

The presence of bone metastases alters the prognosis of patients with differentiated thyroid carcinoma. Our case report underlines the fact that FDG-PET can have an important impact on management in patients with thyroid cancer.
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